{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:25:47Z","timestamp":1790979947043,"version":"4.1.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.cmi.2025.11.026","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T07:49:29Z","timestamp":1764316169000},"page":"416-426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Achieving global immunity against hepatitis A through universal vaccination: a position paper from the European Society of Clinical Microbiology and Infectious Diseases Study Group for Viral Hepatitis"],"prefix":"10.1016","volume":"32","author":[{"given":"Oana","family":"S\u0103ndulescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Roque-Afonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclsen \u00d6zkaya","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha K.","family":"Rajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Alt\u0131ndi\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Daniel","family":"Miron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serta\u00e7","family":"K\u00fc\u00e7\u00fckkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario U.","family":"Mondelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.11.026_bib1","unstructured":"World Health Organization (WHO). Elimination of hepatitis by 2030 [Internet]. Geneva, Switzerland: WHO. Accessed September 14, 2025. Available from: https:\/\/www.who.int\/multi-media\/details\/elimination-of-hepatitis-by-2030."},{"key":"10.1016\/j.cmi.2025.11.026_bib2","series-title":"Hepatitis A vaccines: WHO position paper","year":"2022"},{"key":"10.1016\/j.cmi.2025.11.026_bib3","series-title":"Rapid risk assessment: multi-country outbreak of hepatitis A in the EU\/EEA","year":"2025"},{"key":"10.1016\/j.cmi.2025.11.026_bib4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41572-023-00461-2","article-title":"Hepatitis A virus infection","volume":"9","author":"Van Damme","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.cmi.2025.11.026_bib5","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1128\/JCM.00667-10","article-title":"Epidemiology and genetic characterization of hepatitis A virus genotype IIA","volume":"48","author":"Desbois","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cmi.2025.11.026_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6905a1","article-title":"Prevention of hepatitis A virus infection in the United States: recommendations of the advisory committee on immunization practices, 2020","volume":"69","author":"Nelson","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.cmi.2025.11.026_bib7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/tid.12217","article-title":"Efficacy and safety of hepatitis A vaccination in kidney transplant recipients","volume":"16","author":"Jeon","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.026_bib8","first-page":"343","article-title":"Safety and effectiveness of the new inactivated hepatitis A virus vaccine","volume":"152","author":"Furesz","year":"1995","journal-title":"CMAJ"},{"key":"10.1016\/j.cmi.2025.11.026_bib9","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.vaccine.2021.03.012","article-title":"Safety and immunogenicity of inactivated hepatitis-A vaccine developed by Human Biologicals Institute in two age groups of healthy subjects: A phase I open label study","volume":"39","author":"Susarla","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2025.11.026_bib10","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031716","article-title":"Globalization and the changing epidemiology of hepatitis A virus","volume":"8","author":"Jacobsen","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.cmi.2025.11.026_bib11","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1093\/infdis\/jiae087","article-title":"The burden of hepatitis A outbreaks in the United States: health outcomes, economic costs, and management strategies","volume":"230","author":"Horn","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.026_bib12","series-title":"WHO hepatitis A vaccine global market study, February 2023","year":"2023"},{"key":"10.1016\/j.cmi.2025.11.026_bib13","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3390\/vaccines12020204","article-title":"The shifting epidemiology of hepatitis A in the world health organization western pacific region","volume":"12","author":"Gloriani","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.cmi.2025.11.026_bib14","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2025.11.026_bib15","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a033480","article-title":"Hepatitis A virus genome organization and replication strategy","volume":"8","author":"McKnight","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.cmi.2025.11.026_bib16","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0399-8320(05)82132-3","article-title":"Usefulness of specific IgG avidity for diagnosis of hepatitis A infection","volume":"29","author":"Desbois","year":"2005","journal-title":"Gastroent\u00e9rologie Clin Biol"},{"key":"10.1016\/j.cmi.2025.11.026_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3350\/kjhep.2012.18.1.56","article-title":"Optimal time for repeating the IgM anti-hepatitis A virus antibody test in acute hepatitis A patients with a negative initial test","volume":"18","author":"Hyun","year":"2012","journal-title":"Korean J Hepatol"},{"key":"10.1016\/j.cmi.2025.11.026_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1086\/315701","article-title":"Duration of viremia in hepatitis A virus infection","volume":"182","author":"Bower","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.026_bib19","series-title":"Global hepatitis report","year":"2017"},{"key":"10.1016\/j.cmi.2025.11.026_bib20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2017.08.034","article-title":"Type A viral hepatitis: a summary and update on the molecular virology, epidemiology, pathogenesis and prevention","volume":"68","author":"Lemon","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.cmi.2025.11.026_bib21","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/jvh.13902","article-title":"Hepatitis A hospitalisations in the United States and risk factors for inpatient mortality: a nationwide population study, 1998\u20132020","volume":"31","author":"Wasuwanich","year":"2024","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.cmi.2025.11.026_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41575-020-00361-w","article-title":"Viral hepatitis and pregnancy","volume":"18","author":"Terrault","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cmi.2025.11.026_bib23","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1447-0756.2011.01757.x","article-title":"Fulminant hepatitis A infection in second trimester of pregnancy requiring living-donor liver transplantation","volume":"38","author":"Simsek","year":"2012","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.cmi.2025.11.026_bib24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.vaccine.2012.04.104","article-title":"Long-term protective effects of hepatitis A vaccines. A systematic review","volume":"31","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2025.11.026_bib25","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1128\/jvi.66.4.2208-2216.1992","article-title":"Antigenic structure of human hepatitis A virus defined by analysis of escape mutants selected against murine monoclonal antibodies","volume":"66","author":"Ping","year":"1992","journal-title":"J Virol"},{"key":"10.1016\/j.cmi.2025.11.026_bib26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nature13806","article-title":"Hepatitis A virus and the origins of picornaviruses","volume":"517","author":"Wang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2025.11.026_bib27","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/hep.23778","article-title":"Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells","volume":"52","author":"Neumann","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2025.11.026_bib28","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jhep.2021.04.035","article-title":"Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990\u20132019","volume":"75","author":"Zeng","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.cmi.2025.11.026_bib29","article-title":"Update on the global burden of acute viral hepatitis in 2021: addressing health inequalities","volume":"13","author":"Zhang","year":"2025","journal-title":"Front Public Health"},{"key":"10.1016\/j.cmi.2025.11.026_bib30","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1007\/s12072-021-10232-4","article-title":"The global trends and regional differences in incidence and mortality of hepatitis A from 1990 to 2019 and implications for its prevention","volume":"15","author":"Cao","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cmi.2025.11.026_bib31","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1016\/S1473-3099(17)30392-4","article-title":"Seroprevalence and susceptibility to hepatitis A in the European union and European economic area: a systematic review","volume":"17","author":"Carrillo-Santisteve","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.026_bib32","series-title":"Hepatitis A virus in the EU\/EEA, 1975\u20132014","year":"2016"},{"key":"10.1016\/j.cmi.2025.11.026_bib33","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.33.1700641","article-title":"Hepatitis A outbreak disproportionately affecting men who have sex with men (MSM) in the European Union and European Economic Area, June 2016 to May 2017","volume":"23","author":"Ndumbi","year":"2018","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.cmi.2025.11.026_bib35","doi-asserted-by":"crossref","first-page":"875","DOI":"10.15585\/mmwr.mm7024a2","article-title":"Hepatitis A virus infections among men who have sex with men\u2014eight U.S. States, 2017\u20132018","volume":"70","author":"Foster","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.cmi.2025.11.026_bib36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jcv.2019.05.014","article-title":"Hepatitis A outbreak affecting men who have sex with men (MSM) in central Argentina, occurred in July 2017\u2013April 2018, later than the European outbreak","volume":"117","author":"Mariojoules","year":"2019","journal-title":"J Clin Virol"},{"key":"10.1016\/j.cmi.2025.11.026_bib37","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/jvh.12926","article-title":"Epidemiological characteristics and associated factors of acute hepatitis A outbreak among HIV-coinfected men who have sex with men in Taiwan, June 2015-December 2016","volume":"25","author":"Cheng","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.cmi.2025.11.026_bib38","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/infdis\/jiaa636","article-title":"Hepatitis A person-to-person outbreaks: epidemiology, morbidity burden, and factors associated with hospitalization\u2014multiple states, 2016\u20132019","volume":"223","author":"Hofmeister","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.026_bib39","series-title":"Viral hepatitis: hepatitis A outbreak linked to frozen organic strawberries","year":"2025"},{"key":"10.1016\/j.cmi.2025.11.026_bib40","series-title":"Viral hepatitis: hepatitis A outbreak linked to person-to-person contact","year":"2024"},{"key":"10.1016\/j.cmi.2025.11.026_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jfp.2025.100505","article-title":"Investigation of two outbreaks of hepatitis A virus infections linked to fresh and frozen strawberries imported from Mexico\u20142022\u20132023","volume":"88","author":"McClure","year":"2025","journal-title":"J Food Prot"},{"key":"10.1016\/j.cmi.2025.11.026_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28810","article-title":"Global outbreaks of foodborne hepatitis A: systematic review and meta-analysis","volume":"10","author":"Gandhi","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.cmi.2025.11.026_bib43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.puhe.2022.04.002","article-title":"National report on healthcare utilization and mortality in patients with hepatitis A infection in the United States","volume":"207","author":"Sobotka","year":"2022","journal-title":"Public Health"},{"key":"10.1016\/j.cmi.2025.11.026_bib44","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1016\/j.vaccine.2005.06.022","article-title":"Cell mediated and antibody immune response to inactivated hepatitis A vaccine","volume":"23","author":"Schmidtke","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2025.11.026_bib45","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1002\/jmv.26327","article-title":"Hepatitis A vaccine immunogenicity 25 years after vaccination in Alaska","volume":"93","author":"Ramaswamy","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.cmi.2025.11.026_bib46","first-page":"484","article-title":"Modeling the long-term antibody response and duration of immune protection induced by an inactivated, preservative-free hepatitis A vaccine (Healive) in children","volume":"33","author":"Yu","year":"2020","journal-title":"Biomed Environ Sci"},{"key":"10.1016\/j.cmi.2025.11.026_bib47","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2227549","article-title":"Immunogenicity persistence of hepatitis A vaccines Healive\u00ae and Havrix\u00ae among children: 15 years follow-up and long-term prediction","volume":"19","author":"Wang","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2025.11.026_bib48","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.vaccine.2021.01.038","article-title":"One or two doses of hepatitis A vaccine in universal vaccination programs in children in 2020: a systematic review","volume":"40","author":"Andani","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2025.11.026_bib49","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1086\/505115","article-title":"A Mathematical model of hepatitis A transmission in the United States indicates value of universal childhood immunization","volume":"43","author":"Van Effelterre","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.026_bib50","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1016\/j.vaccine.2021.03.052","article-title":"Using the power law model to predict the long-term persistence and duration of detectable hepatitis A antibody after receipt of hepatitis A vaccine (VAQTATM)","volume":"39","author":"Martin","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2025.11.026_bib51","series-title":"Hepatitis A vaccine","year":"2025"},{"key":"10.1016\/j.cmi.2025.11.026_bib52","series-title":"Hepatitis A: hepatitis A vaccine administration","year":"2025"},{"key":"10.1016\/j.cmi.2025.11.026_bib53","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1080\/21645515.2020.1819742","article-title":"Hepatitis A vaccination and its immunological and epidemiological long-term effects\u2014a review of the evidence","volume":"17","author":"Herzog","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2025.11.026_bib54","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.cmi.2018.11.005","article-title":"Long-term immunogenicity and immune persistence of live attenuated and inactivated hepatitis A vaccines: a report on additional observations from a phase IV study","volume":"25","author":"Luo","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.11.026_bib55","doi-asserted-by":"crossref","first-page":"811.e9","DOI":"10.1016\/j.cmi.2016.06.004","article-title":"Comparison of the safety and immunogenicity of live attenuated and inactivated hepatitis A vaccine in healthy Chinese children aged 18 months to 16 years: results from a randomized, parallel controlled, phase IV study","volume":"22","author":"Ma","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.11.026_bib56","article-title":"The safety, immunogenicity, and immunopersistence of hepatitis A vaccine in HBs-Ag-positive participants: a retrospective study","volume":"11","author":"Wang","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.cmi.2025.11.026_bib57","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jama.294.2.202","article-title":"Incidence of hepatitis A in Israel following universal immunization of toddlers","volume":"294","author":"Dagan","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2025.11.026_bib58","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.294.2.194","article-title":"Incidence of hepatitis A in the United States in the era of vaccination","volume":"294","author":"Wasley","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2025.11.026_bib59","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/14760584.2020.1813575","article-title":"Hepatitis A epidemiology in Latin American countries: a 2020 view from a systematic literature review","volume":"19","author":"Andani","year":"2020","journal-title":"Expert Rev Vaccin"},{"key":"10.1016\/j.cmi.2025.11.026_bib60","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12879-025-10458-9","article-title":"Vaccination status and hepatitis A immunity in children: insights from a large-scale study in Turkey","volume":"25","author":"Yigit","year":"2025","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.026_bib61","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.vaccine.2018.12.054","article-title":"Impact of the single-dose universal mass vaccination strategy against hepatitis A in Brazil","volume":"37","author":"Souto","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2025.11.026_bib62","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1093\/jpids\/piu068","article-title":"Single-dose universal hepatitis A immunization in Argentina: low viral circulation and high persistence of protective antibodies up to 4 years","volume":"4","author":"Vizzotti","year":"2015","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"s2","key":"10.1016\/j.cmi.2025.11.026_bib123","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2893.2008.01032.x","article-title":"Long-term trends in hepatitis A incidence following the inclusion of Hepatitis A vaccine in the routine nationwide immunization program","volume":"15","author":"Chodick","year":"2008","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.cmi.2025.11.026_bib124","doi-asserted-by":"crossref","unstructured":"Levine H, Kopel E, Anis E, Givon-Lavi N, Dagan R. The impact of a national routine immunisation programme initiated in 1999 on Hepatitis A incidence in Israel, 1993 to 2012. Eurosurveillance [Internet]. 2015 Feb 19 [cited 2025 Sept 18];20(7). Available from: https:\/\/www.eurosurveillance.org\/content\/10.2807\/1560-7917.ES2015.20.7.21040.","DOI":"10.2807\/1560-7917.ES2015.20.7.21040"},{"issue":"5","key":"10.1016\/j.cmi.2025.11.026_bib125","doi-asserted-by":"crossref","first-page":"677","DOI":"10.24953\/turkjped.2019.05.006","article-title":"Impact of the mandatory Hepatitis A immunization program: before and after the vaccine in Ankara, Central of Turkey","volume":"61","author":"Kanik-Y\u00fcksek","year":"2019","journal-title":"Turk J Pediatr"},{"issue":"4","key":"10.1016\/j.cmi.2025.11.026_bib126","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/hep.31429","article-title":"Changing Epidemiology of Hepatitis A in China: Evidence From Three National Serological Surveys and the National Notifiable Disease Reporting System","volume":"73","author":"Wang","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2025.11.026_bib63","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.tmaid.2017.12.004","article-title":"An extra priming dose of hepatitis A vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression\u2014a prospective, open-label, multi-center study","volume":"21","author":"Rosdahl","year":"2018","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.026_bib64","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199208133270702","article-title":"A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children","volume":"327","author":"Werzberger","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.11.026_bib65","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1080\/21645515.2018.1539600","article-title":"Safety of two doses of an inactivated hepatitis A vaccine given 6 months apart in healthy toddlers, children, and adolescents aged 12 months to 15 years in China: a phase IV study","volume":"15","author":"Shi","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2025.11.026_bib66","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.vaccine.2003.08.034","article-title":"A post-licensure evaluation of the safety of inactivated hepatitis A vaccine (VAQTA\u00ae, Merck) in children and adults","volume":"22","author":"Black","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2025.11.026_bib67","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40121-019-0230-9","article-title":"Post-marketing surveillance of hepatitis A virus vaccine (Avaxim\u00ae 160U) in South Korea from 2011 to 2015","volume":"8","author":"Kim","year":"2019","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.cmi.2025.11.026_bib68","first-page":"29","article-title":"Immunogenicity and safety of live attenuated hepatitis A vaccine: a multicentric study","volume":"46","author":"Faridi","year":"2009","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.cmi.2025.11.026_bib69","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1080\/21645515.2020.1741997","article-title":"Review of long term immunogenicity and tolerability of live hepatitis A vaccine","volume":"16","author":"Shah","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2025.11.026_bib70","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.4161\/21645515.2014.979646","article-title":"Long term follow-up study to evaluate immunogenicity and safety of a single dose of live attenuated hepatitis A vaccine in children","volume":"11","author":"Mitra","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2025.11.026_bib71","doi-asserted-by":"crossref","first-page":"8302","DOI":"10.1016\/j.vaccine.2020.11.019","article-title":"Long-term seropositivity, safety, and impact of inactivated and live, attenuated hepatitis A vaccines in China\u2014a cross-sectional study","volume":"38","author":"Xiaojin","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2025.11.026_bib72","first-page":"CD009051","article-title":"Hepatitis A immunisation in persons not previously exposed to hepatitis A. Cochrane Hepato-Biliary Group","volume":"2012","author":"Irving","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cmi.2025.11.026_bib74","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taae125","article-title":"Hepatitis A vaccine immunogenicity and boostability in adults receiving immunosuppressive therapy and adults living with HIV: a prospective single-centre cohort study","volume":"32","author":"Schnyder","year":"2025","journal-title":"J Travel Med"},{"key":"10.1016\/j.cmi.2025.11.026_bib75","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jval.2015.02.004","article-title":"Public health impact and cost-effectiveness of hepatitis A vaccination in the United States: a disease transmission dynamic modeling approach","volume":"18","author":"Dhankhar","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.cmi.2025.11.026_bib76","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1016\/j.vaccine.2021.08.087","article-title":"Cost-effectiveness of routine catch-up hepatitis A vaccination in the United States: dynamic transmission modeling study","volume":"39","author":"Elbasha","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2025.11.026_bib77","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1590\/S1413-86702009000400003","article-title":"Hepatitis A: the costs and benefits of the disease prevention by vaccine, Paran\u00e1, Brazil","volume":"13","author":"Zahdi","year":"2009","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.026_bib78","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1016\/j.vaccine.2005.03.021","article-title":"Cost-effectiveness of universal childhood hepatitis A vaccination in Chile","volume":"23","author":"Valenzuela","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2025.11.026_bib79","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1080\/13696998.2024.2384263","article-title":"Healthcare resource utilization and costs associated with hepatitis A in the United States: a retrospective database analysis","volume":"27","author":"Samant","year":"2024","journal-title":"J Med Econ"},{"key":"10.1016\/j.cmi.2025.11.026_bib80","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2893.2008.01029.x","article-title":"Incidence of hepatitis A in Argentina after vaccination","volume":"15","author":"Vacchino","year":"2008","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.cmi.2025.11.026_bib81","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1097\/INF.0000000000001322","article-title":"Single-dose universal hepatitis A immunization in one-year-old children in Argentina: high prevalence of protective antibodies up to 9 years after vaccination","volume":"35","author":"Urue\u00f1a","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2025.11.026_bib82","doi-asserted-by":"crossref","DOI":"10.1590\/1980-549720200073","article-title":"Vacina\u00e7\u00e3o universal contra hepatite A no Brasil: An\u00e1lise da cobertura vacinal e da incid\u00eancia cinco anos ap\u00f3s a implanta\u00e7\u00e3o do programa","volume":"23","author":"Brito","year":"2020","journal-title":"Rev Bras Epidemiol"},{"key":"10.1016\/j.cmi.2025.11.026_bib83","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/23744235.2024.2370975","article-title":"Seroprevalence of hepatitis A virus among people born before and after implementation of universal vaccination in Argentina","volume":"56","author":"Flichman","year":"2024","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.cmi.2025.11.026_bib84","first-page":"1","article-title":"Prevention of hepatitis A through active or passive immunization: recommendations of the advisory committee on immunization practices (ACIP)","volume":"55","author":"Fiore","year":"2006","journal-title":"MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep"},{"key":"10.1016\/j.cmi.2025.11.026_bib85","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/21645515.2017.1264798","article-title":"Effectiveness of hepatitis A vaccination as post-exposure prophylaxis","volume":"13","author":"Parr\u00f3n","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2025.11.026_bib86","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s100960100461","article-title":"Control of a community-wide outbreak of hepatitis A by mass vaccination with inactivated hepatitis A vaccine","volume":"20","author":"Zamir","year":"2001","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.026_bib87","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2017.22.5.30457","article-title":"Ongoing outbreaks of hepatitis A among men who have sex with men (MSM), Berlin, November 2016 to January 2017\u2014linked to other German cities and European countries","volume":"22","author":"Werber","year":"2017","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.cmi.2025.11.026_bib88","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2017.22.5.30454","article-title":"Outbreak of hepatitis A associated with men who have sex with men (MSM), England, July 2016 to January 2017","volume":"22","author":"Beebeejaun","year":"2017","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.cmi.2025.11.026_bib89","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2017.22.8.30468","article-title":"Hepatitis A outbreak among men who have sex with men (MSM) predominantly linked with the EuroPride, The Netherlands, July 2016 to February 2017","volume":"22","author":"Freidl","year":"2017","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.cmi.2025.11.026_bib90","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1186\/s12889-020-09499-3","article-title":"A description of a hepatitis A outbreak in men who have sex with men and public health measures implemented in Seine-Maritime department, Normandy, France, 2017","volume":"20","author":"Nicolay","year":"2020","journal-title":"BMC Public Health"},{"key":"10.1016\/j.cmi.2025.11.026_bib91","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.15585\/mmwr.mm6743a3","article-title":"Hepatitis A virus outbreaks associated with drug use and homelessness\u2014California, Kentucky, Michigan, and Utah, 2017","volume":"67","author":"Foster","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.cmi.2025.11.026_bib92","series-title":"Hepatitis A outbreak toolbox","year":"2019"},{"key":"10.1016\/j.cmi.2025.11.026_bib93","series-title":"Hepatitis A outbreak toolbox","year":"2024"},{"key":"10.1016\/j.cmi.2025.11.026_bib95","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.vaccine.2019.10.057","article-title":"Effect of donor funding for immunization from Gavi and other development assistance channels on vaccine coverage: evidence from 120 low and middle income recipient countries","volume":"38","author":"Ikilezi","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2025.11.026_bib96","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jhep.2020.09.013","article-title":"A global investment framework for the elimination of hepatitis B","volume":"74","author":"Howell","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.cmi.2025.11.026_bib97","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2023-011883","article-title":"COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats","volume":"8","author":"Hotez","year":"2023","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.cmi.2025.11.026_bib98","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12985-025-02645-6","article-title":"Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications","volume":"22","author":"Leong","year":"2025","journal-title":"Virol J"},{"key":"10.1016\/j.cmi.2025.11.026_bib99","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.egyr.2021.12.039","article-title":"Vaccine cold chain management and cold storage technology to address the challenges of vaccination programs","volume":"8","author":"Pambudi","year":"2022","journal-title":"Energy Rep"},{"key":"10.1016\/j.cmi.2025.11.026_bib100","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.vaccine.2016.11.097","article-title":"The origins of the vaccine cold chain and a glimpse of the future","volume":"35","author":"Lloyd","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2025.11.026_bib101","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40124-022-00278-9","article-title":"Vaccine hesitancy: obstacles and challenges","volume":"10","author":"Galagali","year":"2022","journal-title":"Curr Pediatr Rep"},{"key":"10.1016\/j.cmi.2025.11.026_bib102","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1093\/tbm\/ibab128","article-title":"Online misinformation and vaccine hesitancy","volume":"11","author":"Garett","year":"2021","journal-title":"Transl Behav Med"},{"key":"10.1016\/j.cmi.2025.11.026_bib103","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2195786","article-title":"Vaccine co-administration in adults: an effective way to improve vaccination coverage","volume":"19","author":"Bonanni","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2025.11.026_bib104","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41541-024-00809-z","article-title":"Exploring the future adult vaccine landscape\u2014crowded schedules and new dynamics","volume":"9","author":"Jones","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.cmi.2025.11.026_bib105","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.cmi.2023.08.006","article-title":"Coadministered pneumococcal conjugate vaccine decreases immune response to hepatitis A vaccine: a randomized controlled trial","volume":"29","author":"Riekkinen","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.11.026_bib107","series-title":"Revolving fund vaccine prices 2025\u2013PAHO\/WHO","year":"2025"},{"key":"10.1016\/j.cmi.2025.11.026_bib108","series-title":"EACS guidelines","year":"2025"},{"key":"10.1016\/j.cmi.2025.11.026_bib109","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.681449","article-title":"Aging and options to halt declining immunity to virus infections","volume":"12","author":"Palacios-Pedrero","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2025.11.026_bib110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.coviro.2020.09.007","article-title":"Immunity to acute virus infections with advanced age","volume":"46","author":"Nikolich-\u017dugich","year":"2021","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.cmi.2025.11.026_bib111","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001035","article-title":"Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations","volume":"5","author":"Rondaan","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.cmi.2025.11.026_bib112","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/21645515.2016.1246094","article-title":"Immunogenicity of trivalent influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy","volume":"13","author":"Nakashima","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2025.11.026_bib113","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1200\/JCO.19.00354","article-title":"Influenza vaccine effectiveness among patients with cancer: a population-based study using health administrative and laboratory testing data from Ontario, Canada","volume":"37","author":"Blanchette","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cmi.2025.11.026_bib114","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.2215\/CJN.02160311","article-title":"Efficacy of influenza A H1N1\/2009 vaccine in hemodialysis and kidney transplant patients","volume":"6","author":"Crespo","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cmi.2025.11.026_bib115","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1093\/cid\/ciaa1897","article-title":"Immunogenicity and safety of the 9-valent human papillomavirus vaccine in solid organ transplant recipients and adults infected with human immunodeficiency virus (HIV)","volume":"73","author":"Boey","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.026_bib116","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cmi.2021.09.036","article-title":"Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review","volume":"28","author":"Galmiche","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.11.026_bib117","article-title":"Pregnancy and vaccination: guidelines for vaccinating pregnant women","year":"2025","journal-title":"Pubished"},{"key":"10.1016\/j.cmi.2025.11.026_bib118","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/cid\/ciad206","article-title":"A Randomized clinical trial of 1-dose vs accelerated 2-dose schedule for hepatitis A virus (HAV) revaccination among people with human immunodeficiency virus who were nonresponders or had seroreversion after primary HAV vaccination","volume":"77","author":"Chen","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.11.026_bib119","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1016\/j.vaccine.2019.09.043","article-title":"Uptake and safety of hepatitis A vaccination during pregnancy: a vaccine safety datalink study","volume":"37","author":"Groom","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2025.11.026_bib120","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jceh.2021.12.003","article-title":"Vaccination in chronic liver disease: an update","volume":"12","author":"Alukal","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.cmi.2025.11.026_bib121","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1128\/AEM.00619-16","article-title":"Detection and molecular characterization of hepatitis A virus from Tunisian wastewater treatment plants with different secondary treatments","volume":"82","author":"Ouardani","year":"2016","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.cmi.2025.11.026_bib122","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s12560-021-09497-7","article-title":"Hepatitis A outbreaks and environmental circulation of genotype IA strains in the S\u00e3o Paulo City, 2017-2018","volume":"13","author":"Prado","year":"2021","journal-title":"Food Environ Virol"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25005816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25005816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:20:19Z","timestamp":1785363619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25005816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":122,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1198743X25005816"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.11.026","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Achieving global immunity against hepatitis A through universal vaccination: a position paper from the European Society of Clinical Microbiology and Infectious Diseases Study Group for Viral Hepatitis","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.11.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}